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Abstract A significant induction of GTP cyclohydrolase I
(GTPCH) mRNA was observed in lung, heart and kidney of rats 
treated with lipopolysaccharide (LPS; 10 mg/kg i.v.). GTPCH 
mRNA levels in liver were high even in untreated rats, and re- 
mained elevated after LPS treatment. Parallel induction of nitric 
oxide synthase (NOS) mRNA was observed in these tissues of 
LPS-treated rats. Our results demonstrate induction of GTPCH 
mRNA after LPS treatment in vivo and provide molecular evi- 
dence for the increased GTPCH activity which may up-regulate 
NOS activity in vivo. 
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1. Introduction 
Tetrahydrobiopterin (BH4) is an essential cofactor of all 
isoforms of nitric oxide (NO) synthase (NOS) [1]. It was first 
demonstrated that the increase in BH4 levels was crucial for 
cytokine-induced NO production in murine fibroblasts [2]. The 
causal relationship between increased BH4 levels and cytokine- 
induced increase in NO production was confirmed in rat vascu- 
lar smooth muscle cells [3] and a murine macrophage cell line 
[4]. Moreover, recent reports demonstrated that inflammatory 
cytokines increase NOS activity in human endothelial cells se- 
lectively by increasing BH4 levels [5,6]. Thus, NOS can be 
regulated through the availability of BH4. Under these condi- 
tions, cytokines increase GTP cyclohydrolase I (GTPCH) activ- 
ity [3-6], the rate-limiting enzyme for de novo BH4 synthesis 
[7]. Increased GTPCH activity has been also demonstrated in 
tissues of bacterial lipopolysaccharide (LPS)-treated rats [8] in 
which widespread induction of NOS is well documented [%11]. 
We recently showed that LPS and interferon-y increased steady 
state levels of mRNA for GTPCH in rat vascular smooth mus- 
cle cells [12]. This cannot be extrapolated as the mechanism for 
the increase in GTPCH activity of all cell types, but similar 
regulation appears possible in other cell types and in vivo. In 
the present study, we investigated whether LPS treatment in 
vivo induces the expression of GTPCH mRNA to obtain mo- 
lecular evidence responsible for the increased GTPCH activity 
which may up-regulate NOS activity in vivo. 
2. Materials and methods 
2.1. Animal treatment and extraction of RNA 
Male Wistar rats (250 300 g) were injected intravenously with either 
LPS (E. coli type, Serotype 0111 :B4, 10 mg/kg: Sigma, St. Louis, MO) 
*Corresponding author. Fax: (81) (282) 86-4632. 
or saline (1 ml/kg) for endotoxin and control group, respectively. Three 
hours later, the animals were sacrificed by exsanguination, a d various 
organs were removed. The organs were frozen in liquid nitrogen imme- 
diately after excision and stored at -70°C before RNA extraction. 
Total RNA was extracted from lung, heart, liver and kidney using the 
guanidinium isothiocyanate/acid phenol method [13]. 
2.2. Reverse transcription-polymerase chain reaction (RT-PCR) 
RT-PCR was performed by standard methods using 1/.tg total RNA. 
The first strand cDNA was synthesized using random primers and 
M-MLV reverse transcriptase (Promega, Madison, WI, USA) followed 
by PCR amplification using synthetic gene-specific primers for rat GTP 
cyclohydrolase I [12] and murine-inducible NOS (iNOS) [14]. Primers 
used were: GTPCH forward 21-mer, 5'-GGATACCAGGAGACCA- 
TCTCA-3'; GTPCH reverse 21-mer, 5'-TAGCATGGTGCTAGTGA- 
CAGT-Y; iNOS forward 21-mer, 5'-CTGCAGGTCTTTGACGCT- 
CGG-3'; iNOS reverse 21-mer, 5'-GTGGAACACAGGGGTGAT- 
GCT-3'. PCR amplification was performed using a DNA PCR kit 
(Perkin Elmer, Norwalk, CT, USA) according to the following sched- 
ule: denaturation, annealing, and elongation at 95, 55 and 72°C for 30 
s, 30 s, and 1 rain, respectively, for 30 cycles. Parallel amplification of
rat glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was per- 
formed for reference using primers as described [15]. The possible 
contamination f any PCR component was excluded by performing a 
PCR reaction with these components in the absence of RT product in 
each set of experiment (negative control). To verify that the amplifica- 
tion did not proceed from residual genomic DNA, a control PCR 
reaction was done for each RNA using RNA as template. 
2.3. Analysis of PCR products 
PCR products were electrophoresed on a 2% agarose gel containing 
ethidium bromide and visualized by UV-induced fluorescence. The 
intensity of the PCR bands on the negative film of the gel photographs 
was quantified by use of a video densitometer linked to a computer 
analysis ystem (ACI, Kanagawa, Japan). All PCR reactions resulted 
in the amplification ofa single product of the predicted size for GTPCH 
(372bp) and iNOS (741bp). 
2.4. Statistical nalysis 
Data are expressed as mean + S.E.M. of three determinations. A 
Student's unpaired t-test was used to compare mean differences. A level 
of P < 0.05 was accepted as statistically significant. 
3. Results 
The PCR products using GTPCH and iNOS specific primers 
showed clear bands at predicted size of 372 and 742 bp, respec- 
tively. These bands were absent in the PCR-amplified products 
using RNA as template or lacking a cDNA template. This 
indicates that the 372 and 741 bp bands originated from 
mRNA, but not from genomic DNA or other contamination. 
As shown Fig. 1, the GTPCH signal was absent or negligible 
in control ung, heart and kidney. In contrast, a large GTPCH 
signal was detected in control iver as well as LPS-treated lung, 
heart, liver and kidney. While the iNOS signal was absent in 
RNAs from control ung, heart, liver and kidney, a large iNOS 
signal was detected in all RNAs from LPS treated-rats. 
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Fig. 1. Effects of LPS treatment invivo on GTPCH and iNOS mRNA 
expression i  lung, heart, liver and kidney. Total RNA was prepared 
from tissues of rats 3 h after intravenous administration f saline (con- 
trol: LPS(-)) or LPS (10 mg/kg: LPS(+)), and assayed by RT-PCR 
using gene-specific primers. Results using primers pecific for GAPDH 
are shown for comparison. DNA size markers in the left lanes corre- 
spond to: 2000, 1200, 800, 400, 200, and 100 bp. Arrows indicate the 
predicted size of PCR products. 
LPS may act directly to induce GTPCH mRNA in vivo as well. 
LPS also increases interferon-?" and tumor necrosis factor-~ in 
vivo [16], that in turn, may lead to induction of GTPCH 
mRNA. 
LPS induces iNOS in vivo as well as in various cell types 
which produce large quantities of NO and profound vasodila- 
tion; this process has been implicated as the cause of Gram- 
negative septic shock [1,17,18]. Widespread induction of iNOS 
in LPS-treated rat is well documented [9-11]. In the present 
study, we also confirmed a significant induction of iNOS 
mRNA in the rat tissues, which is accompanied by increased 
NO2-/NO3- levels in rat plasma (58.2 + 3.7 vs. 167.7 + 24.8 
~M: mean _+ S.E.M., n = 3) and an induction of Ca2+-independ - 
ent NOS activity in the lung homogenates three hours after LPS 
administration (10 mg/kg, i.v.) [19]. We previously showed 
using rat vascular smooth muscle that immunostimulant- 
evoked BH4 synthesis occurs with a time course that parallels 
that for coinduced NO synthesis and is preceded by an increase 
in GTPCH mRNA [12]. Under these conditions, the intracellu- 
lar concentration of BH4 appears to be rate limiting for NO 
synthesis. Indeed, a significant up-regulation of NO synthesis 
in vascular smooth muscle is observed with administration of
excess BH4, and NO synthesis can be prevented by inhibitors 
of enzymes, such as GTPCH, that participate in BH4 synthesis 
[3,12]. Similar esults have been shown in cultured murine mac- 
rophages [4]. Furthermore, it has recently been shown that 
inflammatory cytokines increase NOS activity in cultured 
human endothelial cells by increasing BH4 levels even in the 
face of falling total enzyme [6]. These observations suggest a 
key role for BH4 in regulation of NO production by both 
constitutive and inducible isoforms of NOS. 
Our preliminary study showed a linear relationship between 
the quantity of total cDNA for PCR and the intensity of the 
PCR product for GTPCH in LPS-treated rat liver. Since the 
quantity of GTPCH cDNA for PCR amplification in each 
sample is considered to vary with the concentration of GTPCH 
mRNA, the PCR signal for GTPCH was regarded as the rela- 
tive abundance of GTPCH mRNA. Moreover, we normalized 
the GTPCH signal relative to corresponding GAPDH signal 
from the same RNA, which was expressed as GTPCH/GAPDH 
ratio. As shown in Fig. 2, the GTPCH/GAPDH ratio in lung, 
heart and kidney was substantially increased by treatment of 
rats with LPS. In contrast, there was no significant difference 
in GTPCH/GAPDH ratio between control and LPS-treated 
liver. 
4. Discussion 
This is the first report to show that LPS treatment in vivo 
induces GTPCH mRNA. Increased GTPCH activity and there- 
fore increased BH4 levels in tissues have previously been shown 
in the rat treated with LPS [8]. This suggests that either LPS- 
induced biopterin synthesis arises from post-translational acti- 
vation of pre-existing GTPCH or GTPCH induction is regu- 
lated by protein de novo synthesis. Our data strongly support 
the latter possibility. LPS and interferon-?" increases GTPCH 
mRNA abundance in cultured vascular smooth muscle cells in 
the presence of a protein synthesis inhibitor, indicating no re- 
quirement for intermediary protein synthesis [12]. Therefore, 
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Fig. 2. Effects of LPS on GTPCH mRNA expression i various tissues. 
The intesity ratio of GTPCH to GAPDH was shown. Data are 
mean + S.E.M. of 3 animals (control: ()pen columns, LPS-treated: 
closed columns). GTPCH/GAPDH in control ung, heart and kidney 
was not shown as the GTPCH signal was too low to be quantified. 
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Wemer-Felmayer t al. reported that biopterin concentra- 
tions of plasma were not significantly increased espite a signif- 
icant increase in biopterin in tissues of LPS-treated rat [8]. They 
suggested that BH4 is kept effectively within the cells. However, 
this suggestion contradicts a recent report showing that BH4 
is a secretory product of vascular endothelial cells [20]. More- 
over, the same authors reported that endothelial cells secrete 
BH4 vectorially into the direction of vascular smooth muscle 
[21]. We also observed the secretion of substantial portion of 
BH4 synthetized by LPS-activated vascular smooth muscle 
cells and macrophages (unpublished ata). Thus, BH4 may 
play a key role in a autocrine/paracrine fashion for supporting 
NOS activity. GTPCH activity appears low levels in tissues 
under normal conditions [8,22]. Therefore, an increase in 
GTPCH activity by activation of GTPCH gene expression may 
be necessary for NOS to exert full activity. Conversely, inhibi- 
tion of GTPCH induction may become an important target for 
pharmacological interventions for NO overproduction, i.e. sep- 
tic and cytokine-induced shock. 
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